Immunocore (IMCR) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and financial position

• Pioneered soluble T-cell receptor bispecifics, achieving first approval in solid tumors.

• Pipeline spans oncology, infectious disease, and autoimmune diseases.

• Strong balance sheet with $800 million, supporting ongoing R&D and pipeline expansion.

• Successful launch of first product, KIMMTRAK, driving financial stability.

Product performance and growth drivers

• KIMMTRAK achieved $146 million in net sales for H1, with 34%-37% year-on-year growth.

• U.S. penetration at 65%, with further growth expected, especially from new launches in Europe and other regions.

• Duration on therapy averages eleven months, exceeding clinical trial results and contributing to revenue.

• Ongoing phase III trials (TEBE-AM and adjuvant) could expand patient base from 1,000 to nearly 6,000.

Clinical development and innovation

• TEBE-AM phase III in cutaneous melanoma includes three arms: KIMMTRAK, KIMMTRAK plus Pembro, and investigator choice, with overall survival as the primary endpoint.

• Early data show durable tumor reduction and long-term survival, with similar metrics in uveal and cutaneous melanoma.

• Brenni demonstrates monotherapy activity in heavily pretreated melanoma, with a disease control rate of 56%.

• PRISM-MEL pivotal study is enrolling, comparing NIVO plus Brenni to standard regimens, with completion expected in 2027.